NCT02875730 (LAMDE) is a Phase 4 clinical trial of Pulse Sequence in Atrial Fibrillation, sponsored by Aspire Foundation.

Who is sponsoring NCT02875730?

NCT02875730 is sponsored by Aspire Foundation.

What drugs are being tested in NCT02875730?

Interventions in NCT02875730: Pulse Sequence, CMRI.

What condition does NCT02875730 study?

NCT02875730 studies Atrial Fibrillation, Cryoablation.

Is NCT02875730 still recruiting?

NCT02875730 is currently completed. Last updated 29 June 2018.

Last reviewed 2018-06-29 · How we verify

NCT02875730: LAMDE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Pilot Investigation Detecting Cryoablation Scar by 3D Late Gadolinium Enhancement

Completed Phase 4 Last updated 29 June 2018

What this trial tests

Phase 4 trial testing Pulse Sequence in Atrial Fibrillation in 10 participants. Completed in 27 April 2018.

Timeline

13 December 2016

Primary endpoint
6 March 2018

27 April 2018

Quick facts

Lead sponsor	Aspire Foundation
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	10
Start date	13 December 2016
Primary completion	6 March 2018
Estimated completion	27 April 2018
Sites	1 location across United States

Drugs / interventions tested

Pulse Sequence
CMRI

Conditions studied

Atrial Fibrillation — all drugs for Atrial Fibrillation →
Cryoablation — all drugs for Cryoablation →

Sponsor

Aspire Foundation

Who can join

Adults 18 to 80, any sex, with Atrial Fibrillation or Cryoablation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective trial investigating the effectiveness of a modified MRI preparatory pulse sequence to improve pulmonary vein isolation visualization.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Atrial Fibrillation

Currently open trials in the same condition.

NCT07429214 — A Study of VARIPULSE Catheter and TRUPULSE Generator With VARIPULSE Pro Software in Participants With PAF or PsAF · NA · recruiting
NCT07271238 — Feasibility Study on the VERAFEYE Imaging and Navigation System for Guided Catheter Ablation Procedures · NA · recruiting
NCT07388108 — Atrial Dyssynchrony to Predict Arrhythmias in the Postoperative Setting of Cardiovascular Surgery. · recruiting
NCT07428967 — AV Node Ablation and CONDUCTion System Pacing for Atrial Fibrillation With Preserved Left Ventricular Function · NA · recruiting
NCT06650995 — AlEX-DHF: Ablation and Exercise in Diastolic Heart Failure · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02875730 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Aspire Foundation
Last refreshed: 29 June 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02875730.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing